Viridian Therapeutics Inc (VRDN) gains 1.56% for July 21

Equities Staff  |

Viridian Therapeutics Inc (NASDAQ: VRDN) shares gained 1.56%, or $0.26 per share, to close Wednesday at $16.91. After opening the day at $17.00, shares of Viridian fluctuated between $17.62 and $16.91. 4,811 shares traded hands a decrease from their 30 day average of 15,254. Wednesday's activity brought Viridian’s market cap to $142,545,280.

Viridian is headquartered in Boulder, Colorado..

About Viridian Therapeutics Inc

Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody in development for thyroid eye disease (TED). Viridian is headquartered in Boulder, Colorado , with research and development operations in Waltham, Massachusetts.

Visit Viridian Therapeutics Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Viridian Therapeutics Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Viridian Therapeutics Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:

Market Movers

Sponsored Financial Content